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Abstract
Background: A national program for the treatment of severe allergic (IgE-dependent) asthma with omalizumab
(OMA) was implemented in Poland in 2013. This observational study evaluated the effectiveness of the Polish OMA
program and monitored asthma control after treatment discontinuation.
Methods: In the first year of the program, 53 patients (23 new/30 continuing treatment) received OMA in the
Barlicki Hospital, Poland. Patients were evaluated at baseline and after 16 weeks of OMA treatment by spirometry,
mean dose of inhaled corticosteroids (ICS) and oral corticosteroids (OCS), number of asthma exacerbations, the
Asthma Control Questionnaire (ACQ), and the Asthma Quality of Life Questionnaire (AQLQ). OMA treatment
responses were determined using the global effectiveness of treatment evaluation scale. Fourteen patients ceased
OMA treatment following ≥36 months of therapy and entered follow up.
Results: All patients treated with OMA de novo for at least 16 weeks had a decrease in asthma exacerbations and
showed a good (15/16, 94 %) or an excellent (1/16, 6 %) response to treatment. We observed a reduction in OCS
dose (≥5 mg/day) in 14/16 (88 %) patients. ACQ and AQLQ scores improved by ≥0.5 points in 15/16 (94 %) and
14/16 (88 %) patients, respectively. After OMA cessation, 11/14 (79 %) patients showed worsening of asthma
control and severe exacerbations.
Conclusions: Patients in the OMA program show significant benefits, including reduced use of OCS, improved
asthma control and quality of life. After OMA discontinuation, frequent severe exacerbations were observed
primarily in patients whose asthma was previously uncontrolled by high OCS doses.
Keywords: Effectiveness, Omalizumab, Severe asthma, Severe asthma exacerbations
Background
Omalizumab (OMA) is a biological drug recommended
by Global Initiative for Asthma (GINA) experts for the
therapy of patients with uncontrolled severe allergic
(IgE-dependent) bronchial asthma [1]. Numerous clin-
ical and observational studies have confirmed the effi-
cacy of OMA in improving asthma control, reducing the
number and severity of exacerbations, decreasing the
need for inhaled (ICS) and oral corticosteroids (OCS)
and rescue medications, as well as improving patients’
quality of life (QoL) [2]. In 2003, the American Food
and Drug Agency (FDA) recommended OMA for use in
patients with moderate-to-severe asthma, and 2 years
later the European Medicines Agency (EMA) approved
its use in countries of the European Union.
On 17 March 2013, the program for the treatment of
severe IgE-dependent bronchial asthma with OMA
funded by the National Health Fund (NHF) was imple-
mented in Poland [3]. Previously, OMA was only avail-
able to a limited group of patients. Nowadays, the access
to the therapy is wider but patients must fulfill strict
program qualification criteria (Table 1).
The aims of the study were to determine the clinical
effectiveness of the OMA treatment program after
16 weeks of therapy in patients receiving the drug for
the first time, and to evaluate asthma control after dis-
continuation of OMA in patients who did not obtain
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consent for participation in the program or had com-
pleted the therapy after 36 months.
Methods
This is an observational, prospective, single-center study.
The patients were diagnosed and treated according to
the routine clinical practice and program requirements
contained in the Appendix to the Minister of Health
Declaration [3].
The Barlicki University Hospital is one of 39 centers
across Poland to implement the program. Currently, this
hospital has the highest number of patients within the
NHF OMA treatment program (i.e., 50 patients or
~19 % of the total number), making it a perfect site for
the study. On 4 April 2013, the first patient referred to
the program in the Barlicki University Hospital was
given the consent of the Qualification Committee for
OMA treatment. From 4 April 2013 to 6 April 2014, 53
patients (23 new and 30 continuing treatment, including
one who moved from another center) were treated
within the OMA program in this hospital. Eleven pa-
tients were treated OMA for more than 36 months (i.e.,
the maximum period of treatment determined by the
Qualification Committee [4]) and therefore, were refused
enrolment. Three other patients were continuing previous
OMA therapy in the program, but were discontinued
when they reached 36 months of treatment.
Evaluation of patients
Patients were evaluated at baseline and after 16 weeks of
the treatment in compliance with program requirements
contained in the Appendix to the Minister of Health
Declaration [3]. On entering the program, a detailed his-
tory was collected from each patient, concerning sensitiza-
tions, asthma control, exacerbations, pharmacotherapy,
complications induced by systemic steroid therapy, and
smoking. Each patient underwent resting spirometry, skin
prick tests (SPT) when possible, and laboratory tests (in-
cluding total serum IgE levels, and optionally to SPT,
allergen-specific IgE (sIgE) tests), All patients completed
the Asthma Control Questionnaire (ACQ) and the
Asthma Quality of Life Questionnaire (AQLQ). Moreover
the mean daily dose of OCS over the last 6 months, the
number of hospitalizations, and the number of severe ex-
acerbations in the previous year were calculated. Monthly
exacerbation rate was calculated according following for-
mula: number of exacerbations/months of observations.
At the 16th week, early effectiveness was assessed based
Table 1 Comparison of the NHF omalizumab (OMA) treatment program regulations with the drug indications
OMA program requirements OMA indications (taken from
the European Medicines
Agency)
Age ≥12 years ≥6 years
tIgE in serum 30–1500 IU/ml 30–1500 IU/ml
Severe allergic asthma with sensitization to whole-year allergens Yes Yes
Uncontrolled asthma despite high-dose ICS plus an additional control
drug
ACQ score > 1.5 points (1/6)a >1000 mcg
BDP-CFC/day + LABA or LTRA or
theophylline
Symptomatic High ICS dose +
LABA
Necessity of using OCS continuously or in bursts Yes minimum of 5 mg of prednisone/day No
Multiple exacerbations ≥3/year (1/6)a Yes
Hospitalizations due to exacerbations Yes (1/6)a Not required
Life-threatening asthma attack in medical history Yes (1/6)a Not required
With airflow limitation FEV1 < 60 % predicted (1/6)a FEV1 < 80 % predicted
Additional criteria AQLQ score < 5.0 points (1/6)a Not required
Contraindications Hypersensitivity to the drug Hypersensitivity to the drug
Co-morbidities inducing severe course of asthma Yesb Not contraindicated
Tobacco Non-smokers – obligatory condition Not contraindicated
Pregnancy Absolutely contraindicated Should not be used during
pregnancy unless clearly
necessary
Contraindications: simultaneous therapy with immunosuppressive
drugs (e.g. methotrexate or cyclosporine), anticancer drugs,
immunoglobulin infusions or other biological drugs
Yes Lack of studies
Abbreviations: ACQ asthma control questionnaire, AQLQ asthma quality of life questionnaire, BDP-CFC inhaled beclomethasone CFC, tIgE total immunoglobulin E
levels, FEV1 forced expired volume in one second, ICS inhaled corticosteroid, LABA long-acting beta-adrenoceptor agonist, LTRA leukotriene receptor antagonist,
OCS oral corticosteroid
aOne of six minor criteria concerning severity and control of asthma; at least three of six criteria have to be fulfilled in order to qualify the patient for the program
bExcept treated severe allergic rhinitis
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on the improvement in ACQ and AQLQ scores, severe
exacerbations rate, and mean daily dose of OCS. Finally,
doctors in charge used a five-point global effectiveness of
treatment evaluation (GETE) scale to assess OMA treat-
ment response in our patients, as outlined previously [5].
The early effectiveness was evaluated only in patients who
de novo received omalizumab to avoid the influence of the
previous treatment on the results.
Inclusion criteria in the OMA program
For inclusion in the OMA program, patients must meet
all major qualifying criteria, and a minimum of three
minor criteria (from a total of six) of severe uncontrolled
allergic bronchial asthma as defined by the NHF (Table 1).
The major criteria qualifying patients for the OMA pro-
gram include: ICS > 1000 mcg/day plus another control
drug, and a minimum 5 mg/day of OCS (calculated as a
mean dose over the 6 previous months). The minor cri-
teria include: ≥ 3 severe exacerbations in the previous year,
hospitalization due to exacerbations in the previous year, a
history of life-threatening exacerbations of asthma, ACQ
score > 1.5 points, AQLQ score < 5 points, and forced
expiratory volume in one second (FEV1) < 60 % predicted.
Ethics
The study was conducted in accordance with the Declar-
ation of Helsinki [6], and local regulations relating to ob-
servational studies. Patients entering the NHF program
gave written consent to participate in the program under
specific terms for obtaining the medical history, per-
forming the physical examination or additional tests (i.e.,
lung tests, blood tests, ACQ, AQLQ), and data collec-
tion. These terms are described in the Appendix to the
Minister of Health Declaration [3]. In addition, patients
gave written consent prior to each time the drug was ad-
ministered, according to the formula developed by the
Coordinating Board at the NHF. The study is based on
the analysis of data collected prospectively in the pro-
gram. The source data were encrypted and the extracted
data were anonymous. The authors obtained the consent
for the study from the ethics committee at the Medical
University of Lodz.
Statistical analysis
Statistical analysis was carried out using the methods of
descriptive statistics. The effectiveness of the interven-
tion was analyzed using a one-sample t test and one-
sample Wilcoxon test for parametric and nonparametric
variables, respectively. Changes in study endpoints were
compared with theoretical values that were predefined
as clinically important. A P <0.05 was considered statisti-
cally significant. Analysis was performed on the available
data only, according to per protocol approach. There were
no missing data for included patients. Analysis was per-
formed using Statistica 8.0 (StatSoft, Inc., Tulsa, USA).
Results
Demographic and clinical profiles of patients enrolled in
the program
In total, 20 men and 33 women, with a mean age of
46 years, were included in the study. The detailed demo-
graphic and clinical data are presented in Table 2.
Briefly, the average duration of severe asthma in patients
enrolled for the program was 13 years. Allergies were
confirmed by the SPT or sIgE tests, and revealed that
the house dust mite was the most frequently sensitizing
allergen (50/53 patients, 94 %) followed by cat allergen
(36/53 patients, 68 %). The mean ICS dose converted to
beclomethasone CFC (BDP-CFC) equivalent was 2900
mcg/day, and the mean OCS dose in prednisone equiva-
lent was 16 mg/day (note: the mean was calculated from
data over the previous 6 months). In the year preceding
enrolment, the mean number of exacerbations in the
group was 5.4/year, and 24 patients (45 %) were hospital-
ized due to exacerbations.
All patients showed high mean daily dose of OCS at
the baseline (Table 2, Fig. 1). Patients most frequently
met 4/6 (47.2 %) of the minor criteria (Fig. 1). The most
frequently fulfilled minor criteria were: ACQ score > 1.5
points, exacerbations ≥ 3 in the previous year, and
AQLQ score < 5.0 points (Fig. 1). The percentage of pa-
tients who met each particular criterion of severe uncon-
trolled allergic bronchial asthma is shown in Fig. 1. The
OMA doses for patients participating in the program
were determined according to the manufacturer’s rec-
ommendations and the drug characteristics (Fig. 1).
Early effectiveness of OMA therapy
Early effectiveness analysis was conducted in de novo pa-
tients only. After 16 weeks, 16/23 (70 %) new patients
treated with OMA were evaluated. One patient failed to
attend the two subsequent meetings and we have lost
contact with her, while the other six patients only received
OMA treatment for a period shorter than 16 weeks. The
evaluation of the effectiveness of the 16-week therapy was
carried out in compliance with the program requirements.
All patients showed good (15/16, 94 %) or excellent (1/16,
6 %) response to the therapy based on the GETE scale
(Table 3). In addition, all patients (100 %) had a decreased
number of exacerbations (Table 3). These two criteria are
obligatory to warrant ongoing OMA treatment. When
evaluating the additional clinical criteria for clinically sig-
nificant improvement, we found 14/16 (88 %) patients
showed a significant reduction (P = 0.0001) in OCS use by
at least 5 mg (Fig. 2, Table 3). In 15/16 (94 %) patients, the
ACQ score was significantly reduced (P = 0.0012) by at
least 0.5 points, and in 14/16 (88 %) patients, the AQLQ
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score was significantly improved (P = 0.0055) by at least
0.5 points (Fig. 2, Table 3). Of these additional criteria,
100 % of patients met at least two out of the three criteria,
and all criteria (3/3) were met by 13/16 patients (81 %).
Finally, 8/16 (50 %) patients achieved a clinical improve-
ment in lung function, i.e., showed a ≥ 200 ml improve-
ment in the FEV1, although for whole group the increase
in FEV1 was not statistically significant (P = 0.5521) (Fig. 2,
Table 3).
Evaluation of asthma control after OMA discontinuation
At the time of the program implementation in the Barlicki
University Hospital, 31 patients with asthma were receiv-
ing OMA treatment. While applications for therapy
continuation were submitted for all patients, 11 patients
were disqualified as their OMA duration had exceeded
36 months. However, in 9/11 (82 %) patients, OMA treat-
ment was reintroduced due to worsening of asthma con-
trol. One patient did not develop severe exacerbation,
Table 2 Demographic and clinical characteristics of patients
who qualified for the NHF omalizumab (OMA) treatment
program
Patients in the program All (n = 53)
Age, years
Mean ± SD 45.8 ± 15.3
Min/Max 16/78
Men, n(%) 20(38 %)
Occupational status, n (%)
Occupational activity 23 (43 %)
Sickness pension 7 (13 %)
Duration of severe asthma, years




Dust mites 50 (94 %)
Moulds 19 (36 %)
Cat 36 (68 %)
Dog 23 (43 %)
Other animals 12 (23 %)
Serum tIgE, IU/ml
Mean ± SD 251 ± 219
Median 174
Min/Max 30/922
N≥ 76 IU/ml, n (%) 40 (76 %)
ICS dose, mcg/day




Regularly useda, n (%) 38 (72 %)
Mean 16 ± 12.6
Median 10
Min/Max 0/50
Complications after OCS, n (%) 30 (57 %)
Arterial hypertension 10 (19 %)
Diabetes 8 (15 %)
Osteoporosis 7 (13 %)
Cataract 3 (6 %)
Glaucoma 2 (4 %)
Cushingoid appearance 9 (17 %)
Adrenocortical insufficiency 1 (2 %)
Other 4 (8 %)
Additional control drugs, n (%)
LABA 47 (89 %)
Table 2 Demographic and clinical characteristics of patients
who qualified for the NHF omalizumab (OMA) treatment
program (Continued)
LTRA 39 (74 %)
SAMA/LAMA 16 (30 %)
Theophylline 12 (23 %)
Severe exacerbations/year, n
Min 3, n (%) 53 (100 %)
Mean ± SD 5.6 ± 4
Median 4
Min/Max 3/24
Hospitalizations in the preceding year, n (%) 24 (45 %)
Life-threatening asthma, n (%) 23 (43 %)
ACQ points




Mean ± SD 3.4 ± 1.2
Median 3
Min/Max 1.6/6.5
FEV1% within normal limits
Mean ± SD 64.6 ± 26.1
Median 59
Min/Max 23/136
Abbreviations: ACQ asthma control questionnaire, AQLQ asthma quality of life
questionnaire, BDP-CFC inhaled beclomethasone CFC, tIgE total
immunoglobulin E levels, FEV1 forced expired volume in one second, ICS
inhaled corticosteroid, LABA long-acting beta-adrenoceptor agonist, LAMA
long-acting muscarinic antagonist, OCS oral corticosteroid, SAMA short-acting
muscarinic antagonist, SD standard deviation
aContinuous intake of at least 6 months
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despite worsening of asthma control. Another patient,
with severe exacerbation, did not arrive for the final visit
of the qualification procedure. A detailed analysis of this
group of patients was presented previously [7].
Twelve patients were admitted to the program tem-
porarily (until they reached a total of 36 months of treat-
ment). Three of these 12 patients have now finished
OMA treatment. In 2/3 (67 %) patients who finished the
treatment, worsening of asthma control and severe exac-
erbations were recorded upon OMA cessation. These
patients went through the qualification procedure again;
one has been given consent for further treatment and
another one is waiting for consent. The third patient has
failed to communicate with us.
Overall 11/14 (79 %) patients whose OMA therapy
was interrupted after ≥ 36 months of treatment showed
worsening of asthma control and severe exacerbations.
Discussion
Patients in the Polish NHF program show significant
benefits (good clinical effectiveness), including reduced
use of OCS and severe exacerbation rate, improved
asthma control and quality of life. Unfortunately after
OMA discontinuation, frequent severe exacerbations
were observed primarily in patients whose asthma was
previously uncontrolled by high OCS doses.
This is the first early report presenting data on the
effectiveness of OMA treatment within the Polish NHF
program. The data were collected from one site only,
but including 20 % of all patients participating in the
program (the largest site in Poland). Besides, all of these
patients had to fulfilled the same inclusion criteria, thus
the population was uniform and the data should be rep-
resentative for Poland. It must be stressed that only a
limited number of patients qualified for the program
due to the high price of the drug and the necessity to
optimize costs in relation to clinical outcomes. All pa-
tients in our study adhered to strict NHF program quali-
fication criteria. These qualification criteria differ from
that of the OMA drug indications (Table 1) and the in-
clusion criteria applied for observational studies [8–21].
Therefore, when comparing the results of this study to
those of others, it is important to note these differences.
In particular, the age of the patients, the parameters de-
scribing severe uncontrolled asthma, and some exclusion
criteria are different for NHF treatment program qualifi-
cation compared to traditional OMA drug indications.
First, the minimum age limit for qualification in the
NHF program (12 years) differs from the OMA drug
characteristics (6 years) (Table 1). While clinical studies
have been performed in a patients as young as six, they
were not included in the NHF program due to uncer-
tainty about the pharmaco-economic factors in this age
group. Second, all our patients in the NHF program
used OCS chronically or frequently. This means that
only severely ill patients, who had not responded to
OCS, were included. Due to this prolonged OCS use, a
high percentage (57 %) of patients presented with diseases
Fig. 1 Percentage of study participants who met major and minor criteria for inclusion in the NHF omalizumab (OMA) treatment program. The
OMA doses, determined according to the manufacture’s recommendations and the drug characteristics, are shown. (ICS, inhaled corticosteroid;
BDP, beclomethasone; SCS, systemic corticosteroids; ACQ, asthma control questionnaire; FEV1, forced expiratory volume in one second)
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relating to OCS effects, including difficult to control
hypertension, Cushingoid, diabetes, and osteoporosis
(Table 2). The remaining criteria for inclusion in the
program were taken from major and minor American
Thoracic Society (ATS) criteria for detection of refractory
asthma [22]. These criteria are not covered in the drug
characteristics, apart from high doses of ICS in combin-
ation with another drug to control asthma and impairment
of lung ventilation. However, the degree of ventilation im-
pairment in the NHF program criteria is more severe than
in the drug characteristics or ATS criteria.
As the NHF program qualification criteria for OMA
treatment are more restrictive compared to the clinical
and observational studies carried out in other countries,
our study cohort is characterized by a more severe
course of asthma [8–21, 23]. At baseline, our study group
is most similar to the French cohort study [8], which
began before OMA was registered in the European Union.
In the French study, OMA therapy was administered to
patients suffering severe and chronic asthma who did not
respond to standard treatment. Our study cohort also
shows a similar asthma severity at baseline to the British
cohort study [19], for which patients were qualified
according to previous criteria endorsed by the National
Institute of Health and Care Excellence (NICE) and the
National Health Service (NHS).
By comparing clinical data (ACQ, AQLQ, OCS dose,
frequency of exacerbations, and hospitalizations) at base-
line to that gathered after 16 weeks of OMA therapy, we
showed that the implementation of the OMA treatment
program in Poland has high clinical effectiveness in
patients with severe bronchial asthma. This is similar to
other studies, which have shown that OMA therapy
results in an improvement in asthma control, QoL, re-
quirement for systemic corticosteroids, and a decrease in
frequency of severe exacerbations [9, 14, 17, 18]. However,
it is difficult to directly compare our results to those ob-
tained in other studies due to differences in the evaluation
of clinical parameters.
The clinical effect of OMA begins from 12–16 weeks
and is maintained in over 90 % of treated patients
(91.4 %) over subsequent weeks [24]. Similar conclusions
were drawn in other real life studies [14, 25]. Therefore,
evaluating OMA efficacy at 16 weeks is justified. In our
Table 3 Preliminary effectiveness of omalizumab treatment in patients within the NHF program
Baseline (n = 16) After 16 weeks (n = 16) Mean differences (95 % CI) Respondersb, n(%) P levelc
Monthly exacerbation ratea
















Mean ± SD 67.6 ± 23.8 73.4 ± 18.9 6,69 (13.27 to 11.64) 8 (50 %) 0.5521
Median 68 76
Min/Max 31/107 41/104
GETE: Excellent/Good, n%) 1 (6 %)/15 (94 %)
a calculated as number of exacerbation/months of observations
b responders were defined as patients with reduced number of exacerbation and or improvement above predefined differences in study end-points: -5 mg, -0.5
points, 0.5 points, 0, 2 l for OCS, ACQ, AQLQ, and FEV1, respectively
ccomparisons with predefined (clinically important) differences
Abbreviations: ACQ asthma control questionnaire, AQLQ asthma quality of life questionnaire, FEV1 forced expired volume in one second, GETE global effectiveness
of treatment evaluation scale, OCS oral corticosteroid, SD standard deviation
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study, we used the GETE scale to evaluate the OMA
treatment response at 16 weeks. In the doctor’s opinion,
all patients in the Polish OMA treatment program
showed either excellent or good treatment response.
This is in agreement with the results from across Poland;
during first year of program OMA treatment was
discontinued in only 9 of 278 qualified patients due to
the lack of adequate response to the treatment or side
effects [26]. However, it is important to note that the
percentage of patients who were evaluated after 16 weeks
of treatment was not noted [26].
Compared to our study that showed 100 % OMA re-
sponse, the percentage of responders (in the GETE scale)
in the INNOVATE study was only 61 % [27]. Similarly,
when data from seven clinical studies (published between
2001 and 2005) was analyzed, ~60 % OMA treatment effi-
cacy was observed [28]. On the other hand, results of
other real life studies revealed a higher level (70–84 %) of
OMA treatment efficacy [9, 14, 17, 18]. These differences
in OMA efficacy may be due to the fact that OMA ther-
apy provides the best advantage for more severe asthma
patients [29]. Such patients may have been excluded from
some previous clinical studies. However, as indicated earl-
ier, patients within the Polish NHF OMA treatment pro-
gram were characterized by more severe asthma than in
other cohorts, and therefore, the high clinical effectiveness
of OMA therapy (100 % response rate) in our cohort is
not surprising.
The optimal duration for OMA therapy remains un-
clear, although it has been estimated theoretically to be
5 years [30]. In the Polish program, OMA therapy is an-
ticipated for 2 years but is not administered longer than
3 years. To date, only a few studies have evaluated
asthma control after OMA discontinuation. We previ-
ously reported that following OMA cessation, some pa-
tients show a gradual worsening of asthma control and
an increase in severe asthma exacerbations after only a
short period (i.e., 7.56 ± 2.67 weeks) [7]. Similarly, a re-
lapse of symptoms after OMA cessation was observed in
the INNOVATE study [31]. In another study of 61
patients whose OMA treatment was discontinued after
almost 2 years (22.7 ± 13.1 months), 55.7 % (34/61) of
patients showed worsening of asthma control (mean
time to the loss of control was 20.4 ± 2.6 months) [32].
OMA was reintroduced in 59 % (20/34) of these pa-
tients, but secondary resistance to OMA was noted in
20 % (4/20) of cases. Although we did not observe a sec-
ondary lack of response to OMA treatment in our study,
it did take longer for some patients to improve, and the
improvement was not as significant as when OMA was
used for the first time.
Only one other study by Nopp et al. has evaluated the
stability of continuous OMA therapy [33]. They studied
patients with severe asthma who were treated with
OMA for 6 years, and subsequently observed for a 3-
year period. None of these patients had previously used
OCS continuously. All the patients responded well to
the treatment, and a 6-year stability of the OMA thera-
peutic effect was observed [33]. While asthma condition
worsened in 6/18 (33 %) of patients 3-years after OMA
cessation, the majority (12/18, 67 %) of patients reported
an improvement in or an unchanged asthma condition
[33]. This is different to our study where we observed a
gradual worsening of asthma control upon OMA cessa-
tion in the majority of patients. However, our cohort of
patients differed from other studies with regards to the
severity of asthma at the time of enrolment and upon
treatment cessation. Therefore, apart from the duration
of the therapy, the course of asthma, the level of re-
sponse to treatment, and other clinical features, can
affect the stability of the response to OMA after its ces-
sation. This indicates that decisions regarding cessation
of OMA treatment should be undertaken individually,
taking into consideration the benefits and risks.
It is estimated that about 1000 severe allergic asthma
patients in Poland could potentially be treated with
OMA [34], but due to the current strict inclusion cri-
teria many patients may not receive the necessary treat-
ment. In addition, GINA and expert panel report 3
(EPR-3) recommendations suggest that OMA should be
Fig. 2 Changes in asthma control questionnaire (ACQ) scores, asthma
quality of life questionnaire (AQLQ) scores, systemic corticosteroid (SCS)
use, and forced expiratory volume in one second (FEV1) after 16 weeks
of omalizumab (OMA) treatment in 16 evaluated patients in the cohort.
Dashed lines indicate the cut off for a clinically significance difference
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included prior to regular OCS treatment. Therefore, in
order to bring the Polish OMA treatment program in
line with the rest of the European Union, the Group of
Experts of the Polish Society of Allergology have pro-
posed that the minimum age limit could be lowered, the
requirement for earlier treatment with systemic cortico-
steroids used continuously or nearly continuously could
be abolished, and the FEV1 threshold value could be
raised [35]. Such measures would see more patients
benefit from the program.
Conclusions
The implementation of the Polish OMA program has
brought the treatment of severe asthma in Poland closer
to standards applied in other countries of the European
Union. The experiences gained by the physicians work-
ing in the Barlicki University Hospital during the first
year of the program demonstrate that patients signifi-
cantly benefit from OMA treatment, which justifies the
continuation of the program.
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